Hims & Hers Health, Inc. (HIMS) Stock Analysis
Score B (Speculative)Growth · Grade B · Bearish
$22.11
$48.21
+118.1%
6/10
B
Growth
Investment Thesis
Pre-profit company with 118% upside to fair value. Quality grade B. Pre-profit — revenue growing but no earnings yet.
Pre-profit company with upside potential, but SMA 200 trend is bearish. Wait for trend reversal before entry.
For New Investors
Consider entry at current levels ($22.11) with conservative sizing (2-5% of portfolio). Pre-profit company — position size should reflect higher uncertainty.
For Current Holders
Hold position if thesis is intact. Monitor revenue growth and cash runway.
Buy if
- Price drops below $33.75 (30% discount to FV)
- Revenue continues to grow >30% QoQ
- Path to profitability becomes visible (improving margins)
Sell if
- Revenue growth decelerates below 15%
- Cash runway drops below 6 months
- Management significantly dilutes shareholders
- Competitive moat weakens
Valuation
Pre-profit blend: ev_revenue $37.02 (50%), analyst_target $27.19 (30%), rule_of_40 $96.24 (20%)
Blended Fair Value
$48.21
Methods
ev_revenue, analyst_target, rule_of_40
Quality Analysis
70/120 points
PRE-PROFIT QUALITY: Grade B (70/100)
Market Sentiment
Wall Street Consensus
$25.00
+13.1% Upside
14 analysts
Range: $12.50 — $60.00
Rating: Hold
Our model aligns with Wall Street consensus.
Trend & Technical
Price ($22.10) is 37.6% below SMA 200 ($35.43). Bearish trend. Caution on entry.
Risk & Reward
Asymmetry Ratio
10.00:1
Expected Return
+135.6%
Bull Upside
+249.0%
Bear Downside
--9.1%
Risk/reward ratio of 10.0:1 (VERY_FAVORABLE). Pre-profit valuations carry wider ranges.
Verdict: Very Favorable
Scenario Analysis
Bear
Base
Bull
Buy Zone & Action Plan
See exact entry zones, stop-loss levels, and a personalized action plan.
AI Executive Summary
Get a detailed AI-written breakdown of the investment thesis, risks, and catalysts.
Technical Analysis
RSI, MACD, moving averages, trend signals, and momentum indicators.
Ask AI about this stock
Chat with our AI analyst to ask questions about valuation, risks, or comparisons.
Frequently Asked Questions
What is the fair value of HIMS?
Based on our multi-method conviction analysis, the estimated fair value of Hims & Hers Health, Inc. (HIMS) is $48.21. This is calculated by blending ev_revenue, analyst_target, rule_of_40 and applying a quality premium of 0% based on the company's fundamentals. The confidence level of this estimate is moderate.
Is HIMS a buy, sell, or hold?
HIMS currently has a SPECULATIVE_HOLD rating with a conviction score of 6/10. Pre-profit company with 118% upside to fair value. Quality grade B. Pre-profit — revenue growing but no earnings yet. Consider entry at current levels ($22.11) with conservative sizing (2-5% of portfolio). Pre-profit company — position size should reflect higher uncertainty..
Is HIMS a high-quality stock?
Hims & Hers Health, Inc. has a quality grade of B (70/120 points), rated as PRE-PROFIT QUALITY: Grade B (70/100). Key metrics include ROE of —%, ROIC-WACC spread of —%, and D/E ratio of 2.3x.
What type of stock is HIMS?
HIMS is classified as a "growth" in our framework. High revenue growth: 59.4%, High P/E: 56.9x, Low dividend (reinvesting): 0.0%, High debt: D/E 2.3x, High beta (cyclical behavior): 2.42
What do Wall Street analysts say about HIMS?
14 Wall Street analysts have a consensus price target of $25.00 for HIMS, representing +13.1% upside. Targets range from $12.50 to $60.00. The consensus recommendation is "Hold". Our model aligns with Wall Street consensus.
What are the risks of investing in HIMS?
The risk/reward asymmetry ratio for HIMS is 10.00:1, rated as Very Favorable. Risk/reward ratio of 10.0:1 (VERY_FAVORABLE). Pre-profit valuations carry wider ranges. The expected return is +135.6%, with bull case upside of +249.0% and bear case downside of --9.1%.
What is the current trend for HIMS?
HIMS is in a bearish trend. Price ($22.10) is 37.6% below SMA 200 ($35.43). Bearish trend. Caution on entry. The technical score is —/100.
Related Stock Analyses
Best Stocks to Buy
Get the complete analysis
Scenario targets, buy zones, action plan, executive summary, technical analysis, and AI chat. All free.
Last updated: May 19, 2026 · Framework version 3.7
This analysis is for informational purposes only and should not be considered financial advice. Always do your own research before making investment decisions.